Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Licitra

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 17, 2019
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinomaW van Boxtel, L D Locati, A C H van Engen-van Grunsven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP Bossi, R Miceli, L D Locati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Tumori|January 24, 2026
Medical decision analysis for personalized oncology at the patient bedsideP G Casali, L Licitra, S Provenzano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impactL D Locati, F Perrone, B Cortelazzi, et al.
Oral Oncology|April 8, 2026
A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)M Cossu Rocca, A Esposito, S Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancerS Cavalieri, F Perrone, R Miceli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2017
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 studyA Psyrri, C Fortpied, G Koutsodontis, et al.
ESMO Open|October 30, 2025
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world studyE Colombo, S Cavalieri, A Vingiani, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|February 17, 2019
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinomaW van Boxtel, L D Locati, A C H van Engen-van Grunsven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP Bossi, R Miceli, L D Locati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Tumori|January 24, 2026
Medical decision analysis for personalized oncology at the patient bedsideP G Casali, L Licitra, S Provenzano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impactL D Locati, F Perrone, B Cortelazzi, et al.
Oral Oncology|April 8, 2026
A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)M Cossu Rocca, A Esposito, S Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancerS Cavalieri, F Perrone, R Miceli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2017
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 studyA Psyrri, C Fortpied, G Koutsodontis, et al.
ESMO Open|October 30, 2025
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world studyE Colombo, S Cavalieri, A Vingiani, et al.
Pageof 11